(Q33825196)

29 July 2017

1 reference

title

Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS. (English)

1 reference

29 July 2017

0 references

Marasco WA

1

1 reference

29 July 2017

LaVecchio J

series ordinal

2

1 reference

29 July 2017

Winkler A

series ordinal

3

1 reference

29 July 2017

publication date

1 December 1999

1 reference

Journal of Immunological Methods

29 July 2017

published in

1 reference

29 July 2017

volume

231

1 reference

29 July 2017

issue

1-2

1 reference

29 July 2017

page(s)

223-238

1 reference

Cooperative inhibition of NF-kappa B and Tat-induced superactivation of human immunodeficiency virus type 1 long terminal repeat

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Resisting resistance: maximizing the durability of antiretroviral therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Change in coreceptor use correlates with disease progression in HIV-1--infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Acute HIV syndrome after discontinuation of antiretroviral therapy in a patient treated before seroconversion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

The trans-activator gene of the human T cell lymphotropic virus type III is required for replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Selective immunoaffinity-based enrichment of CD34+ cells transduced with retroviral vectors containing an intracytoplasmatically truncated version of the human low-affinity nerve growth factor receptor (deltaLNGFR) gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

The trans-activator gene of HTLV-III is essential for virus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Cellular uptake of the tat protein from human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Functions of the proteasome: the lysis at the end of the tunnel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

HIV-1 Tat protein as a potential AIDS vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Viral dynamics of HIV: implications for drug development and therapeutic strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Repression of MHC class I gene promoter activity by two-exon Tat of HIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Control of RNA initiation and elongation at the HIV-1 promoter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Single amino acid change in Tat determines the different rates of replication of two sequential HIV-1 isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Tat protein induces self-perpetuating permissivity for productive HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Advances in quantitative PCR technology: 5' nuclease assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Spontaneous assembly of bivalent single chain antibody fragments in Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-kappa B antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intr

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Use of retroviral vectors for gene transfer and expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Antigenic oscillations and shifting immunodominance in HIV-1 infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Developments in quantitative PCR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Immune Hyperactivation of HIV-1-Infected T Cells Mediated by Tat and the CD28 Pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells and monocytes derived from CD34+ cells transduced with an intracellular antibody directed against human immunodeficiency virus type 1 Tat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

A new foreign policy: MHC class I molecules monitor the outside world

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

A monoclonal antibody defines a novel HIV type 1 Tat domain involved in trans-cellular trans-activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

7 January 2021

Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

7 January 2021

Change in tropism upon immune escape by human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

7 January 2021

Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900159-3

7 January 2021

10.1016/S0022-1759(99)00159-3

Identifiers

DOI

1 reference

29 July 2017

1 reference